- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ICYMI: Notable Topics From the 2022 Asembia Specialty Pharmacy Summit
Topics discussed at the Asembia Specialty Pharmacy Summit, held in May 2022 in Las Vegas, Nevada, touched on projections in specialty pharmacy and value-based payments, as well as experiences gained from the COVID-19 pandemic and evaluation of 340B drug pricing.
Below are some notable highlights from the event.
340B, Biosimilars, and More in the Future of Specialty Pharmacy
Adam Fein, PhD, of Drug Channels Institute, and Doug Long of IQVIA discussed how payers are restricting specialty pharmacy access for patients, and they noted that market shares held by specialty medicines are expected to exceed traditional medicines, particularly with the use of oncology biosimilars rising.
Jayson Slotnik Weighs the Future of Value-Based Payments After the Pandemic
During the pandemic, value-based payment organizations were more successful than fee-for services organizations, and only time and feedback from patients and providers will tell if it will be sustainable for the future, said Jayson Slotnik, partner, Health Policy Strategies, Inc.
Gottlieb, Fein Discuss COVID-19, Accelerated Approvals, and Drug Pricing at Asembia 2022
Scott Gottlieb, MD, and Adam Fein, PhD, spoke on how the United States and CDC were unprepared for the COVID outbreak. They also addressed the potential consequences of accelerated drug approval, such as with the drug aducanumab.
Unpacking Past, Future Hurdles in 340B Drug Pricing
The 340B program has evolved and become more intricate since its inception, calling into question its ability to fulfill the original intention of helping underserved patients, explained Tim Paine, principal consultant at Blue Fin Group.
Hospitals Report Declining Cash Reserves, Increasing Reimbursement Delays and Denials
December 1st 2023A new report highlighting the twin pressures hospitals have faced over the last 18 months shows that as reimbursement delays and denials increased and cash and investments decreased, operating expenses have risen sharply.
Read More
Oncology Onward: A Conversation With Dr Debra Patt of Texas Oncology
August 1st 2023Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Listen
What We’re Reading: UnitedHealth Lawsuit; Fentanyl Crackdown; Global Heat Deaths Increase
November 15th 2023A class action lawsuit was filed against UnitedHealth Group and a subsidiary for allegedly using an algorithm to deny rehabilitation coverage for seriously ill patients; US and China officials are finalizing an agreement to crack down on fentanyl; a study published Tuesday projected global heat deaths to increase by 370% if no action is taken against global warming.
Read More
EOM Shows Awareness of Issues, but Provides No Resources, Says COA’s Nicolas Ferreyros
November 4th 2023The Enhancing Oncology Model is trying to address a number of the systemic challenges oncology faces without giving practices the tools and resources they need, said Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance.
Read More
